Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C33H27NO8 · xNa+ · yH2O
Molecular Weight:
565.57 (anhydrous free acid basis)
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
H2O: 15 mg/mL, clear
originator
Abbott
SMILES string
[Na].[H]O[H].OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc2cccc(Oc3ccccc3)c2)[C@H]4CCCc5ccccc45
InChI
1S/C33H27NO8.Na.H2O.H/c35-30(25-17-27(32(38)39)28(33(40)41)18-26(25)31(36)37)34(29-15-7-10-21-9-4-5-14-24(21)29)19-20-8-6-13-23(16-20)42-22-11-2-1-3-12-22;;;/h1-6,8-9,11-14,16-18,29H,7,10,15,19H2,(H,36,37)(H,38,39)(H,40,41);;1H2;/t29-;;;/m0.../s1
InChI key
VEMCGHRDAPMXLI-VYEUTZPBSA-N
Application
A-317491 sodium salt hydrate has been used to block the P2X3 receptor. It has also been used to block the increased membrane conductance.
Biochem/physiol Actions
A-317491 helps to decrease neuropathic and inflammatory pain by inhibiting the P2X3 receptor-mediated Ca2+ influx.
Novel P2X3 and P2X2/3 receptor antagonist
Features and Benefits
This compound is featured on the P2 Receptors: P2X Ion Channel Family page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Subject to U.S. Patent No. 6,831,193. Sold under license from Abbott Laboratories
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Global Trade Item Number
| SKU | GTIN |
|---|---|
| A2979-25MG | 04061832088624 |
| A2979-5MG | 04061833360132 |